Sweta Garg1, Ashish Garg1, Nitendra K. Sahu1*, Awesh K. Yadav2
1RKDF College of Pharmacy, SRK University, Bhopal, 462026 M.P. India
2Drug Delivery and Nanotechnology Laboratory, Bhagyodaya Tirth Pharmacy College, Sagar, 470002 M. P. India.
*Address for Corresponding Author
Dr. Nitendra K. Sahu
RKDF College of Pharmacy, SRK University, Bhopal, 462026 M.P. India
Objective: In this work, we have introduced a carbon nanomaterial (nanodiamond), to bind with anticancer drug doxorubicin (DOX) with via amide bond conjugation for cancer drug delivery and therapy. Material and Methods: Nanodiamonds (ND) was initially carboxylated by the surface modification along the treatment with strong alkaline solution (H2SO4:HNO3) and then activated the carboxyl moiety of ND with the addition of EDC. Anticancer drugs were bound to the ND through a succession of chemical modifications by adipic acid dihydrazide (ADH). The ND-Drug conjugate was analyzed by Nuclear Magnetic Resonance (1H-NMR) Spectroscopy, Fourier Transform Infrared (FTIR) Spectroscopy and Mass Spectroscopy (MS), Atomic Force Microscopy (AFM), Particle size, Zeta potential, Drug release, SRB assay against MCF-7 cells, and DNA fragmentation. Results: Spectroscopic analysis confirms the conjugation of nanodiamond with different anticancer drug. AFM photomicrograph represents the surface morphological features of ND-DOX conjugates. In- vitro investigation showed that ND-DOX conjugates have slow and sustained drug release characteristics. In-vitro cytotoxicity studies, an enormous cytotoxic potential of ND-Drug conjugates were showed against cancer cell line. Conclusion: Above all findings were suggested that the ND-DOX conjugates may be a potential inhibitor of MCF-7 cancer cells to act as a drug candidate. According to all these data it can be confirm that the ND-DOX conjugates could be an effective agent for drug delivery and could be promising in future for tumor targeting strategy.
Keywords: Nanodiamond, sustained release, drug delivery, cytotoxicity, conjugates